Top Tweets for #ARROS1
⭐️ @OncBrothers deliver again!
🫁#WCLC26 #lungcancer #research highlights for #communityoncology
🤔What are your biggest takeaways?
#NSCLC
#ADAURA
#PAPILLON
#DESTINYLung04
#ARROS1
#HARMONi
#SCLC
#MAVERICK
#DeLLphi
#lcsm #OncTwitter #HemOnc #oncology #MedX @SWOG #MedEd
Highlights from #WCLC26 #CommunityOncology:
NSCLC
1. #ADAURA Update Adj mEGFR
2. #PAPILLON 1L EGFR Ex20
3. #DESTINYLung04 1L mHER2
4. #ARROS1 1L ROS1+
5. #HARMONi 2L mEGFR
SCLC
6. #MAVERICK @SWOG MRI surv
7. #DeLLphi Tarla SubQ & ⬇️ freq
#lcsm #OncTwitter @IASLC
1/8
4. #ARROS1: PhI/II, 1L in TKI naive ROS1+ mNSCLC, Zidesamtinib:
- Approved in 2026 in 2L
- In 1L, ORR: 94%! CR: 15%
- PFS ≥ 12mos: 90%
- Intracranial ORR: 100% 🤯
- Taltrectinib for now is the SoC. Awaiting approval and longer data with Zidesamtinib.
5/8
Waiting on official @FDAOncology but based on PR, Zidesamtinib now @US_FDA ✅ for previously treated #ROS1 NSCLC, ARROS-1 study:
- RR 44%
- DoR 12mos: 69%
- AEs: Edema, neuropathy, constipation, fatigue and dyspnea. But discontinuation rate was very low.
#OncTwitter #lcsm
Highlights from #WCLC26 #CommunityOncology:
NSCLC
1. #ADAURA Update Adj mEGFR
2. #PAPILLON 1L EGFR Ex20
3. #DESTINYLung04 1L mHER2
4. #ARROS1 1L ROS1+
5. #HARMONi 2L mEGFR
SCLC
6. #MAVERICK @SWOG MRI surv
7. #DeLLphi Tarla SubQ & ⬇️ freq
#lcsm #OncTwitter @IASLC
1/8
🚨 A new treatment option is here for patients with ROS1-positive #NSCLC.
Listen as @StephenVLiu, @charocampelo, and @alexdrilon discuss the #FDA approval of zidesamtinib, findings from the #ARROS1 trial, CNS activity, and what this means for the future of ROS1-directed care.
🎧 https://t.co/LRBxT1AV3R
#ROS1 #LungCancer #LungCancerConsidered #FDAApproval #Oncology
🚨🔥@OncoAlert Hot Off The Press
⭐️@US_FDA approves #Zidesamtinib
for locally advanced or metastatic #ROS1+ non-small cell #LungCancer, previously treated with at least one prior TKI.
Approval based on #ARROS1 Trial:
✅#ORR 44%
✅ 12-month DOR: 69%
👇🏻
https://t.co/R5OQWqMNwZ
Exciting #ARROS1 phase 1/2 trial results of #zidesamtinib in ROS+ mNSCLC #WCLC25 @alexdrilon
💠Active in heavily pretreated pts: ORR 44% after 1-4 prior ROS1 TKIs; 51% after 1 prior TKI (criz or entrect)
💠Responses after prior repotrectinib & taletrectinib; active against G2032R
Zidesamtinib in the #ARROS1 study is being presented here at #WCLC25. How will this drug reshape our ROS1 treatment landscape?
What’s missing on the safety slide below? Dizziness 😵💫 @ros1cancer @OncogeneCancer @IASLC
ROS1+ lung cancer is rare, but patients are not invisible. At #WCLC25 Dr @alexdrilon #ARROS1 shows science is working for them too in a pivotal trial for ALL ROS1 patients, w activity in brain mets & TRK-sparing - can mean fewer burdens & longer time on treatment.
#WCLC25
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC.
Learn more about ARROS-1: https://t.co/swUPrvRcGi
#LARVOL #CancerResearch #Oncology #ARROS1 #Zidesamtinib #NSCLC #LungCancer #CancerData #OncologyInsights | @StephenVLiu | @SuyogCancer
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC.
Learn more about ARROS-1: https://t.co/swUPrvRcGi
#LARVOL #CancerResearch #Oncology #ARROS1 #Zidesamtinib #NSCLC #LungCancer #CancerData #OncologyInsights | @StephenVLiu | @SuyogCancer
We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by @BenjaminBesseMD
👉 MTD not reached, RP2D selected (100 mg oral daily)
🔥 ORR 44% in pts who were heavily pretreated (1-4 prior ROS1 inhibitors), 51% if repotrectinib-naive
🔥 ORR 41% in pts who received 2 or more prior ROS1 TKIs
🔥 ORR 38% in pts post-repotrectinib and with ROS1 G2032R mutation (the most common on-target mutation resistant to earlier-generation ROS1 TKIs)
✅ CNS-active with IC-ORR of 50%, including in pts post-lorlatinib / post-repotrectinib
🌟 Safety profile very favorable, well tolerated by pts notably with sparing of TRK-mediated neuro-toxicity (‼️important in the ROS1 treatment landscape‼️)
Encouraging results, warranting further investigation including in TKI-naive and TKI-pretreated settings
👏 Congratulations to @BenjaminBesseMD on the presentation
🙏 Grateful to co-investigators and patients, families and caregivers
@alexdrilon B.C. Cho @DRCamidge @JoelNealMD C.C. Lin @StephenVLiu @MNagasaka S. Kao @EnriquetaFelip A.J. van der Wekken J. Bauman @ShirishGadgeel @ViolaWZhu
@MGHCancerCenter @MassGeneralNews @GustaveRoussy @MSKCancerCenter @ros1cancer #LCSM
Dr @alexdrilon discusses emerging #ROS1 inhibitors @IASLC, including NVL-520. NVL-520 is designed with the aim of addressing brain mets and acquired resistance mutations while avoiding off-target CNS-related adverse events. The #ARROS1 trial of NVL-520 is open: NCT05118789 #LCSM
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers